ADORA1 and heart failure: Two randomized, double-blinded, placebo-controlled clinical trials had been initiated to study the effect of a partial adenosine A1 receptor agonist, neladenoson bialanate, in patients with heart failure and a preserved ejection fraction (≥ 45%) or heart failure with a reduced ejection fraction (≤ 35%).